Esperion Therapeutics (ESPR) to Release Earnings on Thursday

Esperion Therapeutics (NASDAQ:ESPR) is scheduled to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Esperion Therapeutics to post earnings of ($0.14) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $73.83 million during the quarter, compared to analyst estimates of $51.90 million. On average, analysts expect Esperion Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Price Performance

Shares of ESPR stock opened at $2.12 on Wednesday. The stock has a market capitalization of $416.00 million, a PE ratio of -2.47 and a beta of 0.96. The business’s 50 day simple moving average is $1.89 and its 200 day simple moving average is $2.13. Esperion Therapeutics has a one year low of $0.87 and a one year high of $3.40.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 2nd. Needham & Company LLC cut their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Finally, StockNews.com upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, October 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.17.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.